Dr. Ferry et al., ALLOSTERIC REGULATION OF [H-3] VINBLASTINE BINDING TO P-GLYCOPROTEIN OF MCF-7 ADR CELLS BY DEXNIGULDIPINE, Biochemical pharmacology, 49(12), 1995, pp. 1851-1861
Plasma membranes were prepared from the P-glycoprotein expressing huma
n breast cancer cell line MCF-7 ADR. [H-3]Vinblastine bound to these m
embranes saturably with a B-max of 24 pmol/ mg of protein and K-D of 2
3 nM. In contrast, membranes from the parent cells MCF-7 WT, which do
not express P-glycoprotein, did not bind [3H]vinblastine with high aff
inity. Cytotoxics known to be transported by P-glycoprotein inhibited
the binding of [3H]vinblastine, as did multidrug reversing agents incl
uding the 1,4-dihydropyridine, dexniguldipine-HCl (K-i, 15 nM). In dis
sociation kinetic experiments, dexniguldipine-HCl accelerated the diss
ociation of [H-3]vinblastine from P-glycoprotein, indicating a negativ
e heterotropic allosteric mechanism of action through a drug binding s
ite distinct from that of vinblastine. Other 1,4-dihydropyridines test
ed also accelerated [H-3]vinblastine dissociation from P-glycoprotein,
however, multidrug reversing drugs of different chemical classes, inc
luding quinidine, verapamil and cyclosporin A did not. These results s
uggest that P-glycoprotein of MCF-7 ADR cell membranes possesses at le
ast two drug acceptor sites which are allosterically coupled: receptor
site-1 which binds vinca alkaloids, and receptor site-2 which binds 1
,4-dihydropyridines such as dexniguldipine-HCl, which had the highest
affinity of the tested derivatives.